Search Results

There are 19060 results for: content related to: Oncogenic RAF: a brief history of time

  1. You have free access to this content
    Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition

    Pigment Cell & Melanoma Research

    Volume 25, Issue 2, March 2012, Pages: 248–258, W. Deng, Y. N. Vashisht Gopal, A. Scott, G. Chen, S. E. Woodman and M. A. Davies

    Version of Record online : 12 JAN 2012, DOI: 10.1111/j.1755-148X.2011.00950.x

  2. You have free access to this content
    2011 International Melanoma Congress

    Pigment Cell & Melanoma Research

    Volume 24, Issue 5, October 2011, Pages: 990–1075,

    Version of Record online : 10 OCT 2011, DOI: 10.1111/j.1755-148X.2011.00909.x

  3. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition

    Molecular Carcinogenesis

    Hyung Kwon Byeon, Hwi Jung Na, Yeon Ju Yang, Hyeong Ju Kwon, Jae Won Chang, Myung Jin Ban, Won Shik Kim, Dong Yeob Shin, Eun Jig Lee, Yoon Woo Koh, Joo-Heon Yoon and Eun Chang Choi

    Version of Record online : 12 OCT 2015, DOI: 10.1002/mc.22418

  4. You have full text access to this OnlineOpen article
    Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors

    Pigment Cell & Melanoma Research

    Volume 27, Issue 2, March 2014, Pages: 253–262, Jaehyuk Choi, Sean F. Landrette, Tiffany Wang, Perry Evans, Antonella Bacchiocchi, Robert Bjornson, Elaine Cheng, Amy L. Stiegler, Symon Gathiaka, Orlando Acevedo, Titus J. Boggon, Michael Krauthammer, Ruth Halaban and Tian Xu

    Version of Record online : 6 JAN 2014, DOI: 10.1111/pcmr.12197

  5. You have full text access to this OnlineOpen article
    PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells

    Pigment Cell & Melanoma Research

    Volume 23, Issue 2, April 2010, Pages: 190–200, Ruth Halaban, Wengeng Zhang, Antonella Bacchiocchi, Elaine Cheng, Fabio Parisi, Stephan Ariyan, Michael Krauthammer, James P. McCusker, Yuval Kluger and Mario Sznol

    Version of Record online : 10 FEB 2010, DOI: 10.1111/j.1755-148X.2010.00685.x

  6. You have free access to this content
    Melanoma 2010 Congress

    Pigment Cell & Melanoma Research

    Volume 23, Issue 6, December 2010, Pages: 874–1004,

    Version of Record online : 13 OCT 2010, DOI: 10.1111/j.1755-148X.2010.00767.x

  7. You have free access to this content
    KRAS and BRAF: drug targets and predictive biomarkers

    The Journal of Pathology

    Volume 223, Issue 2, January 2011, Pages: 220–230, Efsevia Vakiani and David B Solit

    Version of Record online : 28 OCT 2010, DOI: 10.1002/path.2796

  8. You have free access to this content
    Society for Melanoma Research 2013 Congress

    Pigment Cell & Melanoma Research

    Volume 26, Issue 6, November 2013, Pages: 932–1019,

    Version of Record online : 24 OCT 2013, DOI: 10.1111/pcmr.12166

  9. You have free access to this content
    Society for Melanoma Research 2012 Congress

    Pigment Cell & Melanoma Research

    Volume 25, Issue 6, November 2012, Pages: 836–903,

    Version of Record online : 19 OCT 2012, DOI: 10.1111/pcmr.12023

  10. TGFβ induces epithelial-mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways

    Molecular Carcinogenesis

    Pablo Baquero, Eva Jiménez-Mora, Adrián Santos, Marina Lasa and Antonio Chiloeches

    Version of Record online : 21 SEP 2015, DOI: 10.1002/mc.22415

  11. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation

    The EMBO Journal

    Volume 35, Issue 5, 1 March 2016, Pages: 462–478, Min Hwan Kim, Jongshin Kim, Hyowon Hong, Si-Hyung Lee, June-Koo Lee, Eunji Jung and Joon Kim

    Version of Record online : 14 DEC 2015, DOI: 10.15252/embj.201592081

  12. You have full text access to this OnlineOpen article
    ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma

    Molecular Systems Biology

    Volume 10, Issue 12, December 2014, Marjon A Smit, Gianluca Maddalo, Kylie Greig, Linsey M Raaijmakers, Patricia A Possik, Bas van Breukelen, Salvatore Cappadona, Albert JR Heck, AF Maarten Altelaar and Daniel S Peeper

    Version of Record online : 23 DEC 2014, DOI: 10.15252/msb.20145450

  13. You have free access to this content
    PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas

    Pigment Cell & Melanoma Research

    Volume 23, Issue 6, December 2010, Pages: 820–827, John T. Lee, Ling Li, Patricia A. Brafford, Marcia van den Eijnden, Molly B. Halloran, Katrin Sproesser, Nikolas K. Haass, Keiran S.M. Smalley, James Tsai, Gideon Bollag and Meenhard Herlyn

    Version of Record online : 13 OCT 2010, DOI: 10.1111/j.1755-148X.2010.00763.x

  14. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors

    Pigment Cell & Melanoma Research

    Volume 27, Issue 3, May 2014, Pages: 479–484, Kevin J. Basile, Kaitlyn Le, Edward J. Hartsough and Andrew E. Aplin

    Version of Record online : 10 FEB 2014, DOI: 10.1111/pcmr.12218

  15. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells

    Pigment Cell & Melanoma Research

    Volume 26, Issue 4, July 2013, Pages: 509–517, Kaitlyn Le, Erik S. Blomain, Ulrich Rodeck and Andrew E. Aplin

    Version of Record online : 8 APR 2013, DOI: 10.1111/pcmr.12092

  16. You have free access to this content
    BRAF, a target in melanoma

    Cancer

    Volume 116, Issue 21, 1 November 2010, Pages: 4902–4913, Keith T. Flaherty and Grant McArthur

    Version of Record online : 13 JUL 2010, DOI: 10.1002/cncr.25261

  17. You have free access to this content
    That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance

    British Journal of Pharmacology

    Volume 169, Issue 8, August 2013, Pages: 1708–1722, Matthew J Sale and Simon J Cook

    Version of Record online : 26 JUL 2013, DOI: 10.1111/bph.12220

  18. Identification of direct transcriptional targets of V600EBRAF/MEK signalling in melanoma

    Pigment Cell & Melanoma Research

    Volume 22, Issue 6, December 2009, Pages: 785–798, Leisl M Packer, Philip East, Jorge S Reis-Filho and Richard Marais

    Version of Record online : 4 AUG 2009, DOI: 10.1111/j.1755-148X.2009.00618.x

  19. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of 18F-FDG-PET and 18F-FLT-PET

    Contrast Media & Molecular Imaging

    Volume 10, Issue 3, May/June 2015, Pages: 203–210, Edwin J. W. Geven, Stefan Evers, Tapan K. Nayak, Mats Bergström, Fei Su, Danny Gerrits, Gerben M. Franssen and Otto C. Boerman

    Version of Record online : 9 SEP 2014, DOI: 10.1002/cmmi.1619

  20. Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain

    Pigment Cell & Melanoma Research

    Volume 27, Issue 1, January 2014, Pages: 124–133, Timothy R. Wagenaar, Leyuan Ma, Benjamin Roscoe, Sung Mi Park, Daniel N. Bolon and Michael R. Green

    Version of Record online : 15 OCT 2013, DOI: 10.1111/pcmr.12171